Stockreport

Zenas BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Zenas BioPharma, Inc.  (ZBIO) 
PDF - Obexelimab Phase 3 INDIGO trial topline results in Immunoglobulin G4-Related Disease (IgG4-RD) expected around year-end 2025 - - Reported highly positive 12-week prim [Read more]